Company Profile

Changing the way diagnostics are delivered, Tasso has developed the HemoLink usefuly understood as a virtually painless blood collection device that enables self-collection of blood samples and testing in standard lab instruments. The device sticks on the upper arm with an adhesive and is started by the user pressing the button on the device. After 3 minutes, the device is taken off, the tube removed and sent to the lab. The new approach addresses the issues of difficult draw patients -- patients who dislike needles, or those without ready access to hospitals for lab testing. The firm has good data from a first pediatric use case and has completed and submitted their first FDA clinical trial for use in adults for a lipid panel. With 70% of diagnostic decisions based on diagnostic testing, blood sample collection is a critical part of healthcare provision. HemoLink provides value to patients, labs, and hospital systems. For patients, the painless nature of the device allows for a better experience for a common procedure. For Labs, they have access to more tests without having to expand infrastructure or personnel. For hospital systems, better compliance of patients to do the needed tests can reduce readmissions and lower costs associated with complications.